MYGN Q4 2022 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q4 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$178M+10.6% YoY

Gross Profit

$124M69.7% margin

Operating Income

-$46M-25.9% margin

Net Income

-$42M-23.8% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$22M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$313M

Stockholders' Equity

$886M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$161M	+10.6%
Gross Profit	$124M	$115M	+7.7%
Operating Income	-$46M	-$43M	-6.7%
Net Income	-$42M	-$8M	-456.6%

Geographic Segments

UNITED STATES

$157M88%

Non-US

$21M12%